Why Drug Price Reform Alone Won't Heal America
President Donald Trump's revived effort to reduce prescription drug prices is a long-overdue step toward affordability. For millions of Americans, the cost of staying alive has become burdensome, and any policy that eases the burden is worth celebrating.
However, as a physician, I've seen what happens when medications become too cheap, plentiful, and automatic. If we don't reform how drugs are used, we risk trading financial hardship for clinical harm.
Vagaries of Lower Drug Costs
In today's health care system, medication is the first answer—and often the last, especially for older adults. More than 40
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Obama's doctor says Biden's physician should have given him cognitive tests
Former President Joe Biden's doctor should have given him more cognitive tests, according to the doctor of former President Barack Obama. Jeffrey Kuhlman, who served as Obama's doctor between 2009 and 2013, told the New York Post on Saturday that Biden and any politician over the age of 70 should be given "a few hours" of annual mental exams that should be accessible to the public. 'My position is that a 78-year-old candidate, Trump at the time, an 82-year-old president [Biden] would both benefit from neurocognitive testing,' Kuhlman said. He went on to say that "any politician over the age of 70 has normal age-related cognitive decline," and pointed out that he's been recommending annual mental exams for more than a year. Biden's doctor, Kevin O'Connor, oversaw three physicals for the president during his time in office, but Kuhlman says the physical reports did not include notes from a neurocognitive specialist. He also pointed out that Biden did not take the Montreal Cognitive Assessment, which Donald Trump agreed to take during his first term. That test is a two-minute screening test of about 30 questions that probes for signs of dementia, according to Kuhlman. Obama's doctor said that he had "no doubts" that Trump "aced" the Montreal Cognitive Assessment, but said he believes that the White House should also release the CT scans taken after Trump's attempted assassination last year. While the Montreal test is able to detect some basic signs of dementia, the doctor noted that it wasn't adequate for determining more serious cognitive issues. According to Kuhlman, mental processing speed and spacial visualization all begin to decline around the age of 60. Kuhlman said he respected O'Connor's medical judgement, but added that "sometimes those closest to the trees miss the forest." O'Connor told the New York Post in July 2024 — just days after the then-president announced he would not run for re-election — that Biden's cognitive health was "excellent." Then-White House Press Secretary Karine Jean-Pierre insisted to the public that Biden didn't "need a cognitive test" because he "passes a cognitive test every day." She has since decided to leave the Democratic Party and write a tell-all book about her time in the White House, earning her a savaging by some Democrats. Visitor logs to the White House show that Biden did submit an evaluation form to an expert in Parkinson's Disease, but O'Connor said that the meeting was part of Biden's annual physical. Kuhlman says that the doctor who evaluated Biden in that visit, Kevin Cannard, had been evaluating Biden for 14 years, and that he trusts the doctor's evaluation. O'Connor was subpoenaed by the Republican-led House Oversight Committee on Thursday to stand for questioning about Biden's mental abilities during a hearing on June 27. Shortly after the House investigation was launched, the Trump administration issued a memo stating that it was issuing its own investigation into whether or not people other than Biden used an autopen signature device to sign off on executive actions during the late period of Biden's presidential term. Both investigations follow the release of a book by Jake Tapper and Alex Thompson, titled Original Sin, that alleges a mass coverup of Biden's cognitive impairment by those closest to him.
Epoch Times
6 hours ago
- Epoch Times
Why Drug Price Reform Alone Won't Heal America
President Donald Trump's revived effort to reduce prescription drug prices is a long-overdue step toward affordability. For millions of Americans, the cost of staying alive has become burdensome, and any policy that eases the burden is worth celebrating. However, as a physician, I've seen what happens when medications become too cheap, plentiful, and automatic. If we don't reform how drugs are used, we risk trading financial hardship for clinical harm. Vagaries of Lower Drug Costs In today's health care system, medication is the first answer—and often the last, especially for older adults. More than 40
Yahoo
11 hours ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
